Statins and colorectal cancer: The jury is still out

American Journal of Gastroenterology

Volumn 104, Issue 11, 2009, Pages 2858-2859

  Goldstein, Mark R ^a   Mascitelli, Luca ^b   Pezzetta, Francesca ^c  

^a Fountain Medical Court ^*  (United States)

^b Medical Service   (Italy)

^c Ospedale Civile di Tolmezzo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; HUMAN; IMMUNOMODULATION; LETTER; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT;

AGE FACTORS; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INCIDENCE; MALE; NEEDS ASSESSMENT; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL RATE;

EID: 72049106139     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.485     Document Type: Letter

References (7)

1. Hachem C, Morgan R, Johnson M et al. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol 2009;104:1241-1248
2. + T cells. Atherosclerosis 2008;197:829-839
3. Cruiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-1174
4. Yakirevich E, Resnick MB. Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 2007;25:2506-2508 (Pubitemid 47041221)
5. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 2006;1:e129.
6. Shepherd J, Blauw GJ, Murphy MB, et al., on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630
7. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007;211:144-156